Table 2.

Findings from the masseter inhibitory reflex in COVID-19 patients and healthy subjects.

			Patients	Healthy controls
Latency, ms	Right stimulation	iSP1	15.1 ± 3.2; 11.7–21.6*	12.4 ± 1.9; 9.3–17.1
		cSP1	15.8 ± 3.5; 10.5–21.9**	11.4 ± 0.8; 10.5–13.2
		iSP2	49.8 ± 7.9; 37.2–64.5	48.8 ± 8.1; 33.6–60.6
		cSP2	50.2 ± 8.4; 38.4–65.7	48.5 ± 7.8; 33.6–57.3
	Left stimulation	iSP1	15.4 ± 3.6; 11.7–24.9**	11.8 ± 1.2; 9.6–14.4
		cSP1	15.1 ± 3.2; 10.5–23.1**	12.0 ± 1.4; 10.2–15.3
		iSP2	48.0 ± 8.4; 34.5–62.1	49.4 ± 6.2; 40.8–61.5
		cSP2	48.5 ± 7.8; 32.7–61.8	48.4 ± 7.0; 37.8–63.0
Duration, ms	Right stimulation	iSP1	18.5 ± 11.0; 9.6–56.1	14.5 ± 2.7; 10.2–18.9
		cSP1	17.8 ± 11.4; 9.6–56.1	13.6 ± 3.6; 9.0–23.3
		iSP2	34.0 ± 8.7; 22.2–52.8	35.7 ± 8.3; 24–50.1
		cSP2	33.1 ± 10.1; 19.2–53.4	38.5 ± 8.4; 25.2–48.6
	Left stimulation	iSP1	19.0 ± 12.2; 10.5–59.4	14.3 ± 2.7; 10.2–18.6
		cSP1	19.7 ± 11.2; 12.0–54.6	14.9 ± 2.9; 10.2–19.2
		iSP2	34.3 ± 8.8; 25.5–57.0	39.7 ± 8.3; 19.5–49.8
		cSP2	35.6 ± 8.2; 21.9–54.3	39.4 ± 4.6; 33.3–48.9

Mean values ± SD and 95% confidence intervals are showed. The 95% confidence intervals recorded in the healthy controls correspond to the normative value range.

^*p < 0.05,

^**p < 0.01.

cSP1, contralateral early silent period; cSP2, contralateral late silent period; iSP1, ipsilateral early silent period; iSP2, ipsilateral late silent period.